Mauro, Francesca R., Irene Della Starza, Monica Messina, Gianluigi Reda, Livio Trentin, Marta Coscia, Paolo Sportoletti, Lorella Orsucci, Valentina Arena, Gloria Margiotta Casaluci, Roberto Marasca, Roberta Murru, Luca Laurenti, Fiorella Ilariucci, Caterina Stelitano, Donato Mannina, Massimo Massaia, Gian Matteo Rigolin, Lydia Scarfò, Monia Marchetti, Luciano Levato, Monica Tani, Annalisa Arcari, Gerardo Musuraca, Marina Deodato, Piero Galieni, Valeria Belsito Patrizi, Daniela Gottardi, Anna Marina Liberati, Annamaria Giordano, Maria Chiara Molinari, Daniela Pietrasanta, Veronica Mattiello, Andrea Visentin, Candida Vitale, Francesco Albano, Antonino Neri, Lucia Anna De Novi, Maria Stefania De Propris, Mauro Nanni, Ilaria Del Giudice, Anna Guarini, Paola Fazi, Marco Vignetti, Alfonso Piciocchi, Antonio Cuneo, and Robin Foà. 2023. “High Rate of Durable Responses With Undetectable Minimal Residual Disease With Front-Line Venetoclax and Rituximab in Young, Fit Patients With Chronic Lymphocytic Leukemia and an Adverse Biological Profile: Results of the GIMEMA Phase II LLC1518 – VERITAS Study”. Haematologica 108 (8). Pavia, Italy, 2091-2100. https://doi.org/10.3324/haematol.2022.282116.